Turnkey mRNA therapeutics: what is behind Nutcracker Therapeutics’ technology

SOPHIA ANTIPOLIS, France – April 20, 2022 | During recent decades, biopharmaceuticals have gained considerable attention as revolutionary therapeutics and vaccine strategies, attempting to fulfil the high expectations of resolving serious health conditions. Regarding nucleic acids, mRNA-based technologies have been established as promising approaches in therapy and prevention of numerous diseases. mRNA’s great potential can[…]

Stellantis and Mercedes-Benz place their pawns in the solid-state battery game. Here’s what the patents tell us

SOPHIA ANTIPOLIS, France – February 16, 2022 | New rules and regulations on vehicle CO2 emissions are forcing car manufacturers to accelerate their transition towards electric vehicles. Electric vehicle performances (autonomy, speed, safety) mainly rely on batteries. That’s why car manufacturers are massively investing in the battery field, either by improving their own R&D and[…]

Luminar’s patent portfolio supporting Mercedes-Benz’ strategic move toward LiDAR adoption in automotive applications

SOPHIA-ANTIPOLIS, France – February 4, 2022 | In January 2022, Mercedes-Benz, the consumer brand of Daimler, acquired a stake in Luminar Technologies equaling about 1.5 million shares, less than 1% of the company (see here). Such an acquisition results in the collaboration between two important players in the LiDAR for automotive patent landscape. Indeed, on[…]

Silicon Carbide (SiC) patents support the emergence of a complete domestic supply chain in China

SOPHIA-ANTIPOLIS, France – January 20, 2022 | Silicon Carbide (SiC) power devices hold great promise as the electric vehicle (EV) market gets better and better, with forecasts announcing a double-digit annual growth rate for the next decade. Indeed, most EV makers are integrating or evaluating the use of SiC power devices in different EV systems[…]